February 10, 2009 - Dilon Technologies Inc. said today it had record sales for 2008 highlighted by the strongest fourth quarter in the company's history, achieving a 35 percent increase in sales from 2007 to 2008 as molecular breast imaging gains nationwide exposure and acceptance.
Breast-Specific Gamma Imaging (BSGI) - a molecular imaging procedure, along with breast MRI, are expected to increase at a compound growth rate of 28 percent over the next five years, according to the Millennium Research Group's U.S. Markets for Women's Health Imaging Systems report. It also states that Dilon Technologies is leading the way to global availability of molecular breast imaging. Dilon's cornerstone product, the Dilon 6800 Gamma Camera is a high-resolution, compact gamma camera designed to perform BSGI.
Dilon's molecular imaging technology is already available in Europe, parts of the Asian-Pacific basin, the Caribbean, and soon to be in Latin America. In addition, Dilon continues to pursue new alliances with companies such as Terason (Terason t3000 Ultrasound System) and PenRad (PenRad Mammography Information System) to help deliver advanced diagnostic solutions to doctors and patients.
For more information: www.dilon.com